二肽基肽酶-IV抑制剂诱发大疱性类天疱疮：一例报告及欧洲药物警戒数据库中报告病例的分析
Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database.
作者信息
García M, Aranburu M A, Palacios-Zabalza I, Lertxundi U, Aguirre C
机构信息
Basque Country Pharmacovigilance Unit, Galdakao-Usansolo Hospital, Galdakao, Spain.
Mutriku Primary Health Care, Mutriku, Spain.
出版信息
J Clin Pharm Ther. 2016 Jun;41(3):368-370. doi: 10.1111/jcpt.12397.
WHAT IS KNOWN AND OBJECTIVE
Bullous pemphigoid has been reported in association with gliptins. We describe a case, review the literature and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance.
CASE SUMMARY
A 74-year-old woman, treated with vildagliptin/metformin for 12 months, developed bullous pemphigoid, confirmed by skin biopsy. The symptoms resolved within 7 months after vildagliptin/metformin withdrawal.
WHAT IS NEW AND CONCLUSION
A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease.
已知信息与目的
已有报告称大疱性类天疱疮与格列汀类药物有关。我们描述了一例病例，回顾了相关文献，并分析了欧洲药物警戒数据库EudraVigilance中记录的所有大疱性类天疱疮病例。
病例摘要
一名74岁女性，接受维格列汀/二甲双胍治疗12个月后患上大疱性类天疱疮，经皮肤活检确诊。停用维格列汀/二甲双胍后7个月内症状缓解。
新发现与结论
在EudraVigilance中的一项检索显示，除阿格列汀外，大疱性类天疱疮与格列汀类药物之间存在不成比例的关联。这些发现扩展了将格列汀类药物与这种潜在严重疾病相关联的证据。
Zotero 插件